Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DERM | US
0.15
2.51%
Healthcare
Biotechnology
30/06/2024
18/10/2024
6.12
6.02
6.14
5.82
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane an oral isotretinoin drug to treat severe recalcitrant acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi a topical minocycline treatment for inflammatory lesions; Ximino an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets minocycline hydrocholoride capsules and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech Inc.
View LessPositive Momentum
Strength based on increasing price with high volume
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
65.2%1 month
56.9%3 months
68.2%6 months
70.1%47.08
17.21
11.52
2.02
0.35
21.68
1.62
-
5.38M
126.85M
126.85M
-
-19.70
-
-13.50
14.92
2.10
2.03
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.33
Range1M
1.90
Range3M
2.68
Rel. volume
1.62
Price X volume
592.75K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Inventiva S.A | IVA | Biotechnology | 2.63 | 137.71M | 8.68% | n/a | -115.26% |
Century Therapeutics Inc. Common Stock | IPSC | Biotechnology | 1.6 | 135.55M | 1.91% | n/a | 25.38% |
Checkpoint Therapeutics Inc | CKPT | Biotechnology | 3.01 | 135.50M | 1.35% | n/a | 0.00% |
CRDF | CRDF | Biotechnology | 2.9 | 134.99M | 3.94% | n/a | 3.52% |
Outlook Therapeutics Inc | OTLK | Biotechnology | 5.31 | 125.61M | 3.31% | n/a | -39.11% |
Fennec Pharmaceuticals Inc | FENC | Biotechnology | 4.54 | 124.23M | -2.37% | 64.86 | -2193.44% |
Coya Therapeutics Inc. Common Stock | COYA | Biotechnology | 8 | 121.77M | -2.68% | n/a | 0.00% |
PDS Biotechnology Corporation | PDSB | Biotechnology | 3.25 | 119.66M | 4.84% | n/a | 78.85% |
ELEDON PHARMACEUTICALS INC | ELDN | Biotechnology | 2.97 | 117.78M | 5.69% | 6.60 | -7.70% |
Adagene Inc. | ADAG | Biotechnology | 2.61 | 117.73M | 8.30% | n/a | 36.29% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.28 | 92.70M | 0.72% | 5.16 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.48 | 90.67M | 0.91% | 14.48 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 21.68 | 0.53 | Expensive |
Ent. to Revenue | 1.62 | 3,967.00 | Cheaper |
PE Ratio | 47.08 | 41.03 | Par |
Price to Book | 11.52 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 68.20 | 72.80 | Par |
Debt to Equity | 2.02 | -1.23 | Expensive |
Debt to Assets | 0.35 | 0.25 | Expensive |
Market Cap | 126.85M | 3.66B | Emerging |